Evidence and Guidelines TECHNOLOGY 2016 Tina Kader, MD
|
|
- Sheryl Maxwell
- 5 years ago
- Views:
Transcription
1 Evidence and Guidelines TECHNOLOGY 216 Tina Kader, MD Staff endocrinologist Jewish General Hospital Certified Diabetes Educator Montreal, Quebec
2 AACE/ACE 215 Guidelines Glucose Monitoring: When, How, and In Whom? A1c measurement 2 or more times each year in all individuals with diabetes 4 or more times each year in individuals not at target All patients using insulin should perform SMBG Minimum twice daily Ideally, before any insulin injection More frequent checks after meals or middle of the night may be required for patients with frequent hypoglycemia Consider CGM for patients with T1D and T2D on basal-bolus therapy Improve A1c levels Reduce hypoglycemia CGM=continuous glucose monitoring; SMBG=self-monitoring of blood glucose Handelsman Y, et al. Endocrine Practice. 215;21(suppl 1):1-87.
3 Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria: eli lilly sanofi; medtronic; novonordisk;merck BMS; Astraxeneca;Jansen; Takeda Consulting fees: eli lilly sanofi; medtronic; novonordisk;merck Other: [insert company/organization name(s) here]
4 DIABETES AND TECHNOLOGY CANADIAN GUIDELINES FOR CBGM HOW ACCURATE ARE OUR CURRENT TOOLS CASE PRESENTATION WHAT IS AGP; COMING TO YOU SOON WHAT TECHNOLOGY IS HERE AND WHAT IS COMING
5 DIABETES AND TECHNOLOGY CANADIAN GUIDELINES FOR CBGM HOW ACCURATE ARE OUR CURRENT TOOLS CASE PRESENTATION WHAT IS AGP; COMING TO YOU SOON WHAT TECHNOLOGY IS HERE AND WHAT IS COMING
6 Dr. Kader [Poll #2] How would you rank the adherence of your patients to the recommended frequency of SMBG? A. Poor B. Fair C. Good D. Excellent
7 Daily SMBG is not usually required if: C. DAILY SMBG IS NOT USUALLY REQUIRED if the person with diabetes: Is treated only with lifestyle AND is meeting glycemic targets Has pre-diabetes guidelines.diabetes.ca 1-8-BANTING ( ) diabetes.ca Copyright 213 Canadian Diabetes Association
8 Increased frequency of SMBG may be required: B. INCREASED FREQUENCY OF SMBG MAY BE REQUIRED if the person wit diabetes is: SITUATION SMBG RECOMMENDATION Using drugs known to cause hypoglycemia (e.g. sulfonylureas, meglitinides) Has an occupation that requires strict avoidance of hypoglycemia Not meeting glycemic targets Newly diagnosed with diabetes (< 6 months) Treated with lifestyle and/or oral agents AND is meeting glycemic targets SMBG at times when symptoms of hypoglycemia occur or at times when hypoglycemia has previously occured SMBG as often as is required by employer SMBG 2 times per day, to assist in lifestyle and/or medication changes until such time as glycemic targets are met SMBG 1 time per day (at different times of day) to learn the effects of various meals, exercise and/or medications on blood glucose Some people with diabetes might benefit from very infrequent checking (SMBG once or twice per week) to ensure that glycemic targets are being met between A1C tests guidelines.diabetes.ca 1-8-BANTING ( ) diabetes.ca Copyright 213 Canadian Diabetes Association
9 Regular SMBG is required: A. REGULAR SMBG IS REQUIRED if the person with diabetes is: SITUATION Using multiple daily injections of insulin ( 4 times per day) Using an insulin pump Using insulin < 4 times per day guidelines.diabetes.ca 1-8-BANTING ( ) diabetes.ca Copyright 213 Canadian Diabetes Association SMBG RECOMMENDATION SMBG 4 times per day (see page 2 QID [basalbolus/mdi]) SMBG at least as often as insulin is being given (see page 2 premixed or basal insulin only) Pregnant (or planning a pregnancy), whether using insulin or not SMBG individualized and may involve SMBG 4 times per day Hospitalized or acutely ill Starting a new medication known to cause hyperglycemia (e.g. steroids) SMBG individualized and may involve SMBG 2 Experiencing an illness known to cause hyperglycemia times per day (e.g. infection)
10 Monitoring with Meaning SMBG accompanied by structured educational program to facilitate behaviour change results in improved outcomes Teach patients 1. How and when to perform SMBG 2. How to record the results 3. Meaning of various BG levels 4. How behaviour and actions affect SMBG results 1.Parkin CG et al. J Diabetes Sci Technol. 29;3: Polonsky WH, et al. Diabetes Care. 211;34: guidelines.diabetes.ca 1-8-BANTING ( ) diabetes.ca Copyright 213 Canadian Diabetes Association
11 DIABETES AND TECHNOLOGY CANADIAN GUIDELINES FOR CBGM HOW ACCURATE ARE OUR CURRENT TOOLS CASE PRESENTATION WHAT IS AGP; COMING TO YOU SOON WHAT TECHNOLOGY IS HERE AND WHAT IS COMING
12 Causes of glucose variability Kildegaard J, et al: JDST 29, 3(4):
13 Overview of Glucose Monitoring and Assessment Methods A1c SMBG CGM Benefits Reliable estimate of mean BG 3-month average (retrospective) Indicator of complication risk Information on a single point in time Easily measured at home Continuous real-time glucose values Built-in glucose alarms/alerts Limitations Laboratory test Does not capture trends in glycemic variability Misleading in various medical conditions Depends on patient adherence and frequency and timing of measurement Complex interpretation of data Accessibility Cost A1c: glycated hemoglobin; SMBG: self-monitoring blood glucose; CGM: continuous glucose monitoring; AGP: ambulatory glucose profile; BG: blood glucose AGP Comprehensive view of changing glucose patterns over past 14 days Visual summary report of a multitude of glucose measurements Non proprietary Accessibility Cost
14 A1c in Combination with SMBG Glucose (mmol/l) Patient A: A1c 7.% Checks qam (fasting) What if he checked more often? 8 AM 2 PM 8 PM 2 AM 8 AM Patient B: A1c 7.% Checks 4x/d What if he checked more often? 8 AM 2 PM 8 PM 2 AM 8 AM More frequent SMBG gives you a more complete picture
15 Glucose VARIABILITY and Hypoglycemia Increasing glycemic variability is correlated with more frequent episodes of hypoglycemia 1-3 : Reduced peaks and troughs, should result in a lower likelihood of patients slipping below their target range. Less time below target means less risk of hypoglycemia. Reduced glucose variability and flux, will reduce the risk of HbA1c-independent mortality and morbidity. 1. Monnier L et al: Diabetes Technol Ther 211, 13: Qu Y et al: Diabetes Technol Ther 212, 14: Catherine Gorst et al; Diabetes Care 215, 1:2337dc
16 How frequently do you recommend obtaining information from CGM in your insulin-treated patients with T2D? A. Rarely B. Sometimes C. Often D. Routinely E. never
17 DIABETES AND TECHNOLOGY CANADIAN GUIDELINES FOR CBGM HOW ACCURATE ARE OUR CURRENT TOOLS CASE PRESENTATION WHAT IS AGP; COMING TO YOU SOON WHAT TECHNOLOGY IS HERE AND WHAT IS COMING
18 Mr. Cross Type 1 diabetes Age 48 Diagnosed at age 6 Labile glycemia for years DKA; seizures Multiple admissions CURRENT MEDICATIONS Insulin lispro via CSII (insulin pump) Basal rates U/hr Boluses 1U/7g to 1U/11g; ISF = 2.8 to 3.4 Rosuvastatin 1 mg QD Perindopril 2 mg QD LABS A1c 7.2% FPG 6.8 mmol/l LDL-C 1.8 mmol/l ACR 2.5 mg/mmol egfr >6 ml/min
19 Mr. Cross CGM Report Basal Maximum Basal2. U/hr Rate Temp Basal TypePercent of Basal Standard (active) 24-Hour Total U TIMEU/hr :.7 3:.65 7:.55 1: : :.35 2:.5 Pattern A 24-Hour Total -- TIMEU/hr ---- Pattern B 24-Hour Total -- TIMEU/hr ---- Data Sources: Paradigm Veo (813483) Bolus Maximum Basal Rate 1. U Dual/Square (Variable) On Blood Glucose Reminder Off Easy (Audio) BolusOff Entry (Step).1 U Bolus WizardOn Unitsg, mmol/l Active Insulin Time (h:mm) 4: Carbohydrate Insuline Concentration-- Insulin Sensitivity Ratio (mmol/l per U) (g/u) TIMERatio TIMESensivity :9. 6:11. :2.8 11:9. 4:3.4 18:7. 12:3.4 18:3. 22:2.8 Missed Bol us Reminder Off StartEnd (h:m (h:mm) m) ---- Blood Glucose Target (mmol/l) TIMELow High : : : Show different settings, e.g., basal rates on exercise or work days, I:C ratios, ISF and pump settings Sensor Sensor On Transmitter ID BG UnitsMmol/L Glucose AlertsOn TIME Low (mmol/l) High (mmol/l) : Alert Repeat Predictive Alert On :3 2: Low High (mins) Rate Alert: Fall Rise (mmol/l/min).2.2 AUC Limit: Low High (mmol/l) Missed Data/Weak Signal (h:mm).3 Graph Timeout (h:mm).2 Auto Calibration Off Calibration Reminder (h:mm) 1: Calibration (Alert) Repeat (h:mm) 1: Utilities Alert Type Vibrate Low Suspend (mmol/l) 3.3 Low Reservoir Warning Insulin Units Amount 2 U
20 INSULIN PUMP 11 3 SETTINGS BASAL RATE CARB RATIO INSULIN SENSITIVITY
21 BASAL RATE CAN CHANGE BASAL RATE EVERY HOUR USUALLY 4 A DAY SUFFICE USUALLY LOWER AT MIDNIGHT AND HIGHER AFTER 3 AM; DAWN PHENOMENA BASAL RATE DURING THE DAY MAY FLUCTUATE CAN DECREASE ONE HOUR BEFORE EXERCISE
22 INSULIN CARB RATIO ONE UNIT FOR? CARBS START IS ONE UNIT FOR 1 GRAMS SOME NEED LESS; IE LEAN ACTIVE 1 UNIT FOR 2 OBESE 1 UNIT FOR 5 SO IF 1/5 IF EATS 4 GRAM ; 4/5 = 8
23 INSULIN SENSITIVITY SLIDING SCALE USUALLY 2 TO 3 IE 1 UNIT WILL DROP SUGAR BY 2 MMOL IF TARGET IS 8; SUGAR IS OVER 2; 4 UNITS EXTRA IS GIVEN
24 Indications for CSII Poor control despite MDI Frequent hypoglycemia Dawn phenomenon Shift work Athletic; work benefit Lifestyle choice or personal preference CSII: continuous subcutaneous insulin infusion; MDI: multiple daily insulin injections Bruttomesso D, et al. Diabetes Metab Res Rev 29;25: Lassmann-Vague V, et al. Diabetes Metab 21;36:79-85.
25 Contraindications or Cautions for CSII Lack of motivation Psychiatric issues Little or no self-monitoring of blood glucose Active proliferative retinopathy Magnetic fields in environment Frequent DKA CSII: continuous subcutaneous insulin infusion DKA: diabetic ketoacidosis Bruttomesso D, et al. Diabetes Metab Res Rev 29;25: Lassmann-Vague V, et al. Diabetes Metab 21;36:79-85.
26 Mr. Cross CGM Report Glucose (mmol/l) Glucose (mmol/l) 24-Hour Glucose Sensor Overlay Readings & Averages (mmol/l) AM 2 AM 4 AM 6 AM 8 AM 1 AM 12 PM 2 PM 4 PM 6 PM 8 PM 1 PM 12 PM Displays mean glucose Time values of day Glucose Sensor Overlay Bedtime to Wake-Up and Meal Periods Readings & Averages (mmol/l) Bedtime Demonstrates to Breakfast: 6: AM - Wake-up 1: AM post-prandial Lunch: 11: AM - Dinner: 4: PM - 3: PM 1: glucose PM excursions Sensor Interrupt Bedtime: 8: PM - Meals Avg Carbs: Analyzed: 34g 14 Meals Avg Carbs: Analyzed: 26g 8 Meals Avg Carbs: Analyzed: 24g 26 trace ed : AM Wake-up: 5: AM - 9: AM Avg Insulin: 3.1U Avg Carbs/Insulin: 11.2g/U Data Sources: Paradigm Veo (813483) Breakfast Lunch Dinner Avg Insulin: 2.7U Avg Carbs/Insulin: 9.7g/U Avg Insulin: 3.3U Avg Carbs/Insulin: 7.3g/U PC supper glucose is most concerning may require adjustment = Time of meal of I:C ratio 8 PM 9 AM -1: +1: +5: -1: +1: +5: -1: +1: +5: Avera ge
27 Mr. Cross CGM Report Glucos e (mmol/ L) Carbs Insulin (U/hr) (g ) Breakf ast Lunch Dinner Breakf ast Lunch Dinner Breakf ast Lunch Dinner Breakf ast Lunch Dinner Breakf ast Wednesday 1/1 Thursday 1/2 Friday 1/3 Saturday 1/4 Sunday 1/5 Lunch Dinner Glucos e (mmol/ L) Carbs Insulin (U/hr) Glucos e (mmol/ L) Carbs Insulin (U/hr) (g ) (g 9 E.g., October 6 demonstrates over- treatment of 632 Saturday 1/11 Sunday 1/12 Monday 1/13 Tuesday 1/14 ) Monday 1/6 Tuesday 1/7 Wednesday 1/8 Thursday 1/9 Friday 1/1 Useful patient teaching tool Displays basal, bolus, carbs and daily fluctuations hypoglycemia in the evening 12 AM 6 AM 12 PM 6 PM 12 AM 6 AM 12 PM 6 PM 12 AM 6 AM 12 PM 6 PM 12 AM 6 AM 12 PM 6 PM 12 AM 6 AM 12 PM 6 PM 12 AM Sensor trace Interrupted BG reading Off chart Data Sources: Paradigm Veo (813483) Basa ltemp basal Bolu s Suspend Low Suspend Time change Injected insulin (U) Exercis e Other
28 Mr. Cross CGM Report Hypoglycemic Episodes 2 1 Hypoglycemic Episodes, by preceding Event Type - Threshold: 3.9 mmol/l Hyperglycemia Nocturnal Preceding Hypoglycemia Hypoglycemia (11PM-5AM) Basal Rate Increase Bolus Wizard Food Bolus Rapid Falling Sensor Rate of Change Multiple Correction Boluses Most Common Event Types preceding Hypoglycemia Bolus with Corr. Bolus with Falling SensorFalling Sensor Rate of Change Rate of Change Hyperglycemic Episodes 1 5 Hyperglycemic Episodes, by preceding Event Type mmol/l Bolus Wizard Bolus with Rising SensorOvercorrectionBolus Wizard Dawn Food Bolus Rising SensorRate of Change of Override (-) Phenomenon Rate of ChangeWithout BolusHypoglycemia (3AM-7AM) Basal Rate Decrease Most Common Event Types preceding Hyperglycemia Threshold: Delayed Site Change 64 Hyperglycemia 15 Nocturnal 33 Basal Rate Increase Preceding Hypoglycemia Event Type Hypoglycemia Descriptions (11PM-5AM) Event Types % Description Hyperglycemia Preceding Hypoglycemia 78 Consider assessing your patient s insulin sensitivity factors. Consider counseling your patient on the management of hyperglycemia. Nocturnal Hypoglycemia (11PM- 5AM) 44 Consider assessing overnight basal rates and counseling your patient on evening boluses. Basal Rate Increase 44 Consider assessing your patient s basal rate settings, Other Observations including temporary basal rates. No overall issues observed. Data Sources: Paradigm Veo (813483) 69 Bolus Wizard Food 37 Bolus with Rising Bolus Sensor Rate of Change Event Type Descriptions Event Types % Description Bolus Wizard Food Bolus Bolus with Rising Sensor Rate of Change Rising Sensor Rate of Change Without Bolus 17 Rising Sensor Rate of Change Without Bolus 43 Consider assessing the Bolus Wizard settings, counseling your patient on accurate carbohydrate counting, and/or the timing of insulin delivery with respect to carbohydrate intake. 37 Consider counseling your patient to modify bolus amounts when sensor glucose values are rising (upward arrow is present). 22 Consider counseling your patient on bolus use with meals and/or correcting rapid glucose excursions. Displays periods of hypoglycemia after hyperglycemia Change in ISF may be required May require carb counseling or revision of I:C ratios
29 Mr. Cross AGP Report er: AGP is a single report with comprehensive view of changing data ove Glucose (mmol/l) 1 Target Range : Lowest glucose readings are between 2:am-8:am Median curve rises after lunch 2: 4: 6: 8: 1: 12: Glucose values are widely spread indicating glucose variability 14: 16: 18: Median curve is moving up and down, indicating glucose variability 2: 22: : Time of day
30 Mr. Smith Type 2 Diabetes 58 years old T2D x 15 yrs Poor glycemic control for years Neuropathy Retinopathy Exam normal except for reduced monofilament Variable adherence to SMBG Aware of carb counting and prandial insulin CURRENT MEDICATIONS Insulin glargine 4 qhs Insulin aspart 1 U/1 g ac meals; ISF=2 Atorvastatin 2 mg QD Ramipril 1 mg QD LABS A1c 8.8% FPG 12.6 mmol/l LDL-C 2. mmol/l ACR 1.1 mg/mmol egfr 55 ml/min
31 Mr. Smith - SMBG Logbook Pre Breakfast Mon Tues Wed Thur Fri Sat Sun Current insulin regimen: glargine 4 qhs, aspart 1 U/1 g ac meals; ISF=2 Pre Lunch Pre Supper Bed Notes hypo at night hypo at night
32 What would you recommend for Mr. Smith? a. Increase insulin glargine b. Ask Mr. Smith to increase frequency of SMBG for more information c. Initiate CGM for more glucose information d. Obtain an AGP for more glucose information e. Other
33 DIABETES AND TECHNOLOGY CANADIAN GUIDELINES FOR CBGM HOW ACCURATE ARE OUR CURRENT TOOLS CASE PRESENTATION WHAT IS AGP; COMING TO YOU SOON WHAT TECHNOLOGY IS HERE AND WHAT IS COMING
34 Assessing More Frequent Glucose Data Glucose (mmol/l) : 8: 1: 12: 14: 16: 18: 2: 22: : 2: 4: Time of day Continuous Glucose Monitoring (CGM) Continuous real-time glucose values Device measures glucose levels in interstitial fluid Generates a spaghetti view report Glucose (mmol/l) Target Range 4. 4 : 2: 4: 6: 8: 1: 12: Time of day CGM: continuous glucose monitoring; AGP: ambulatory glucose profile 14: 16: 18: 2: 22: : Ambulatory Glucose Profile (AGP) Algorithm developed by the IDC (International Diabetes Centre) Single report with statistical summary, visual display and daily views of glucose information Analyzes glucose data collected over days/weeks as if they occurred within a single 24-hour period Provides a comprehensive view of changing glucose levels/patterns over 14 days
35 Interpretation of Mr. Smith s AGP Glucose (mmol/l) 12 1 Target 9 Range th and 75 th percentiles Median curve rises after meal Wide IQR indicates glucose variability 4: 6: 8: 1: 12: 14: 16: 18: 2: 22: : 2: 4: Time of day 1 th and 9 th percentiles
36 Mr. Smith's AGP Glucose (mmol/l) Target Range Median curve 3 25 th and 1 th and 75 th percentiles 4: 6: 8: 1: 12: 14: 16: 18: 2: 22: : 2: 4: Time of day 9 th percentiles
37 DIABETES AND TECHNOLOGY CANADIAN GUIDELINES FOR CBGM HOW ACCURATE ARE OUR CURRENT TOOLS CASE PRESENTATION WHAT IS AGP; COMING TO YOU SOON WHAT TECHNOLOGY IS HERE AND WHAT IS COMING
38 CGM Devices available in Canada Wired and Wireless Continuous SensorsInstall Transmitter MiniLink Transmitter Implantable Sensors
39
40
41 Conclusions PUMP USE IS ON THE RISE BE AWARE OF BASIC PARAMETERS CONTINUOUS TESTING IS COMING BE AWARE OF AGP AND HOW TO INTERPRET WE WILL SOON BE THE MOST MONITORED AND PICTURED GENERATION
Welcome to CareLink Pro
Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2007 Medtronic MiniMed. All rights reserved. 6025274-0U2 120707 CareLink Pro Report Reference Guide 0 p.2 Sensor
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2009 Medtronic MiniMed. All rights reserved. 6025274-012_a CareLink Pro Report Reference Guide 0 p.2 Adherence
More informationOneTouch Reveal web app Report Reference Guide
OneTouch Reveal web app Report Reference Guide Your step-by-step guide to setting up and using the OneTouch Reveal web app OneTouch Verio meter OneTouch Verio Flex meter OneTouch Verio IQ meter OneTouch
More informationMedical Education. Personal Continuous Glucose Monitoring Protocol. Innovating for life.
Personal Continuous Glucose Monitoring Protocol A Guide to Continuous Glucose Monitoring Integrated with Insulin Pump Therapy Includes Alert and Trend Management as well as Threshold Medical Education
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationBREAKDOWN OF THE CARELINK REPORTS GETTING STARTED WITH CARELINK PERSONAL SOFTWARE
BREAKDOWN OF THE CARELINK REPORTS GETTING STARTED WITH CARELINK PERSONAL SOFTWARE TABLE OF CONTENTS GETTING STARTED WITH CARELINK PERSONAL SOFTWARE Introducing CareLink Personal Software Before You Start...
More informationREPORT INTERPRETATION
REPORT INTERPRETATION: Interpreting ipro Professional Continuous Glucose Monitoring (CGM) Reports and Making Therapy Adjustments TARGET AUDIENCE The audience for this section is physicians, mid-level practitioners,
More information31 days Wed Nov 15, Fri Dec 15, 2017 N/A. Hypoglycemia. Sensor usage (CGM) Mahlon's glucose data was in the target range about 77% of the day.
Mahlon Lovett Overview Report Generated at: Thu, Feb 8, 2018 12:42 PM EST 137 26 N/A 18% 75% 7% Days with CGM data Avg. calibrations per day 3% 1 / 31 0.0 0% Average glucose Standard Hypoglycemia Time
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationMaking the Most of Continuous Glucose Monitoring
Making the Most of Continuous Glucose Monitoring Gary Scheiner MS, CDE Owner & Clinical Director Integrated Diabetes Services LLC Wynnewood, PA AADE 2014 Diabetes Educator of the Year gary@integrateddiabetes.com
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationReport reference guide. mmol/l. One. solution EMR. No fuss
Report reference guide mmol/l One solution No fuss 0000000000 00 0 0000 00 0 0 0 0 0 0 000000000 0 0 00 0 0 0 00 00 0 0 0 0 0 0 00 00000000000000000000 00 EMR About diasend. Plug Transmitter into your
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationPROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY
PROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY Situations Requiring Special Consideration and Resource Documents Second Edition MiniMed 67G System Medical Education TABLE OF CONTENTS A PROTOCOL FOR HYBRID
More informationInterpreting the charts & graphs
Report reference guide mg/dl The diasend solution Interpreting the charts & graphs diasend is a universal cloud-based diabetes data management system, that enables you to upload data from meters, pumps
More informationReal-Time Continuous Glucose Monitoring: From Application to Evaluation
Real-Time Continuous Glucose Monitoring: From Application to Evaluation Gary Scheiner MS, CDE Owner/Director, Integrated Diabetes Services 333 E. Lancaster Ave., Suite 24 Wynnewood, PA 1996 (877) 735-3648
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationUnderstanding the CareLinkTM Sensor Meter Overview Report: Page 1
Understanding the CareLinkTM Sensor Meter Overview Report: Page 1 Sensor & Meter Overview (1 of 3) 4-Hour Glucose Sensor Overlay - Readings & Averages (mg/dl) 1 Glucose Sensor Overlay Bedtime to Wake-Up
More informationHow I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary
How I use the latest technology to investigate and treat a person with Type 1 Diabetes Dr Pratik Choudhary Disclosures Advisory board and speaker fees from Medtronic, Roche, Abbott and Johnson and Johnson,
More informationSelf-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool
Self-Monitoring Blood Glucose () Pattern Recommendation: Basal Insulin Only (To Target) NPH or long-acting analogue, typically given at. at least as often as is being given. Optional, less frequent can
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationContinuous Glucose Monitoring
Continuous Glucose Monitoring What is Continuous Glucose Monitoring? Blood glucose meters measure glucose in your blood and glucose sensors measure glucose levels in the fluid around the cells They are
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationSignificant HbA1c reduction for type 2 diabetes, now clinically proven *
Insulin Pump Significant reduction for type 2 diabetes, now clinically proven * OpT2mise: a landmark study, showing significant reduction of for T2 diabetes patients using pump * * Reznik Y. Cohen O. Aronson
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationDiabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018
Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018 Pumps & Sensors & Meters, Oh My! A Tale of Two Meters Technology for glucometers
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationWhat is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?
What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationRELEASED. first steps. Icon Icon name What it means
Icon Icon name What it means Connection The connection icon appears green when the Sensor feature is on and your transmitter is successfully communicating with your pump. The connection icon appears gray
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationUSING THE MINIMED 670G SYSTEM. Instructions for the Experienced MiniMed 630G System User
USING THE MINIMED 670G SYSTEM Instructions for the Experienced MiniMed 630G System User This is a supplemental guide. For complete instructions and safety information, please see your MiniMed 670G System
More informationUSING THE MINIMED 670G SYSTEM
USING THE MINIMED 670G SYSTEM Instructions for the Experienced MiniMed 630G System User USING THE MINIMED 670G SYSTEM: INSTRUCTIONS FOR THE EXPERIENCED USER Checklist for starting on your MiniMed 670G
More informationCARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT CARELINK REPORTS GUIDE
CARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT CARELINK REPORTS GUIDE CARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT As part of your diabetes therapy you have
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationInsulin pump therapy. Healthy Living with Diabetes
Insulin pump therapy Healthy Living with Diabetes 1 AGENDA Why Insulin Pump Therapy Pump Therapy Overview Benefits of Pump Therapy Getting Started on Pump Therapy 2 WHY INSULIN PUMP THERAPY UMPWHY INSULIN
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationOptimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL
Optimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL Welcome and Introduction Orlando, FL August 7 th, 2014 Keri Weindel,
More informationGetting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite
Getting Started with Insulin Pump Therapy for the MiniMed 530G with Enlite Learning Guide PUMP Foundations MiniMed 530G Insulin Pump Settings Form: We recommend that you record all settings on this form
More informationEmerging Automated Insulin Delivery Systems
Emerging Automated Insulin Delivery Systems Richard M. Bergenstal, MD International Diabetes Center Park Nicollet & HealthPartners Minneapolis, MN Presenter Name 1 Dualities: Richard M. Bergenstal, MD
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationGlycemic Control IU Health Diabetes Centers
Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationAdjusting Insulin Doses
Adjusting Insulin Doses Everyone with diabetes, including you, will need to adjust your insulin doses at some time. There are several reasons why a person may need an insulin adjustment. These reasons
More informationParadigm/Guardian CGM Screens. CareLink Online Reports. Make Your Own Jackson Pollack. CGM by Jackson Pollack. How To Read CGM Screens/Reports
CGM by Jackson Pollack One Pollack sold for $140 million in 1996! Make Your Own Jackson Pollack How To Read CGM Screens/Reports For only $1,000! Paradigm/Guardian CGM Screens On-Screen Reports 3 / 6 /
More informationCASES DR TINA KADER MCGILL JGH; LMC CVPH CDE
CASES DR TINA KADER MCGILL JGH; LMC CVPH CDE Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria:
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationCGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117
CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationMaking Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017
HSW1 Disclosure to Participants Making Sense of Glucose Monitoring Alison B. Evert, MS, RD, CDE UW Neighborhood Clinics UW Medicine Seattle, WA Conflict of Interest (COI) and Financial Relationship Disclosures:
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationUNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE
UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE The insulin pump Replaces injections Delivers insulin through a soft cannula
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationPATIENT TRAINING CHECKLIST MINIMED 670G SYSTEM
Technical Training Insulin Pump Infusion Set: Insulin Pump Model: BASIC FEATURES Patient has demonstrated understanding of: Button Functions Home Screen Menu review Status Screens Battery type/insertion
More informationssociation of Children s Diabetes Clinicians Clinicians Continuous Glucose Monitoring (CGM) Training for Healthcare Professionals and Patients
ssociation of Children s Diabetes Continuous Glucose Monitoring (CGM) Training for Healthcare Professionals and Patients 1 ssociation of Children s Diabetes Contents Chapter Page no. STEP 1...3 Getting
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationInsulin 301: Case, after case, after case
Insulin 301: Case, after case, after case Learning objectives By the end of this session, you will be able to : 1. List the 3 types of insulin, 3 insulin regimens and pros/cons of each 2. Select the regimen
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationORIGINAL ARTICLE. Use of Freestyle Libre Pro TM Flash Glucose Monitoring System in Different Clinical Situations at a Diabetes Centre
18 Journal of The Association of Physicians of India Vol. 65 August 217 ORIGINAL ARTICLE Use of Freestyle Libre Pro TM Flash itoring System in Different Clinical Situations at a Diabetes Centre Bangalore
More informationApplications of Technologies to Your Patient. Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington
Applications of Technologies to Your Patient Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington Disclosures Consultant: Abbott Diabetes Care, Roche
More informationContinuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients
ssociation of Children s Diabetes Continuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients 1 ssociation of Children s Diabetes Contents Chapter Page no. Chapter
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationWHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?
Christian In better control with his pump since 2012 WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Many people with Type 1 diabetes worry about potential long-term
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationHow to Transfer Your Settings
How to Transfer Your Settings for your Replacement MiniMed 530G System Let s get started! Step 1: Before you send your original pump back, copy your current settings onto the Insulin Pump Settings Form.
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationCalgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations
Calgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations This is a long and important document. It lists the steps for starting insulin pump therapy at the Calgary Diabetes Centre. It
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More information15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016
15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016 Sponsored by: Abbott Diabetes Care and Lilly Diabetes Type 1 and exercise Royal Berkshire Hospital Centre for Diabetes and Endocrinology
More informationVIRTUAL PATIENTS DERIVED FROM THE
VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationEvolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk
Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationInsulin Pumps - External
Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of
More informationIn general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.
1 2 3 In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 4 Answer: b and c Many alcohol containing drinks
More informationEAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK. Optimising Glycaemic Control for Children and Young People with Diabetes
EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK Optimising Glycaemic Control for Children and Young People with Diabetes Local diabetes teams need to take on the responsibility of ensuring
More informationPrior to making any insulin adjustments the following knowledge and skills are required:
Diabetes Control Diabetes Control Food, activity and insulin influence your blood glucose levels. At times it may seem like a juggling act as you attempt to balance these three factors. Home blood glucose
More informationAnalyzing Glucose Data
Analyzing Glucose Data Objectives Identify when insulin needs to be adjusted Identify pattern of high and low BGs Provide sources of information on how to adjust insulin Titrate insulin doses based on
More informationLearning Objectives. What does CGM really mean? Cool Groovy Mom. Chief Green Mountain. Certified Grease Monkey. Colon Goo Monster
A Beginner s Guide to Continuous Glucose Monitoring (CGM) Learning Objectives Become familiar with the various options and components/function of CGM systems Discuss the clinical benefits and limitations
More informationHow to Transfer Your Settings
How to Transfer Your Settings for your Replacement Paradigm REAL-Time Revel Insulin Pump Let s get started! Step 1: Before you send your original pump back, copy your current settings onto the Insulin
More information